The effects of lidoflazine and flunarizine on cerebral reactive hyperemia

The effect of Dotarizine (Ca2+ channel blocker) on cerebral vessel reactivity in animals subjected to hyperventilation and anoxia

Dotarizine--a novel piperazine derivative--belongs to wide spectrum Ca+ channel antagonists. It was reported to have strong vasodilatory and antiserotoninergic activities. Unlike other Ca+ channel blockers Dotarizine was found to have lower oral toxicity. In the presented study the influence of the oral administration of the novel compound on the blood flow velocity changes in different cerebral arteries--in basilar artery (BA) and middle cerebral artery (MCA)--was investigated under hyperventilation and hypoxic conditions of rabbits. In the first experimental group 25 mg/kg of Dotarizine dissolved in 0.25% agar was administered orally three times at the 10 hours' intervals. The sham group of animals was fed with agar of the same concentration. The results revealed that oral administration of Dotarizine diminished the vasoconstrictive effect of hyperventilation and this was more pronounced in MCA than in BA. During anoxic conditions stronger vasodilatory effects were observed in both groups of vessels and the low value of pulsatility index (PI) reflected pronounced decrease of the peripheral resistance, in comparison to the control group. Thus, the oral administration of Dotarizine decreases the peripheral resistance of cerebral vessels and therefore seems to have influence on the minute arteries of cerebrovascular system of the brain.

Effect of dotarizine on CO2-dependent cerebrovascular reactivity

Dotarizine is chemically related to calcium antagonist cinnarizine and flunarizine. The study presented investigates the influence of the drug on the diameter of cortical arteries and cerebral blood velocity measured in the MCA in two groups of anaesthetized cats. Changes of vessel diameter were measured indirectly using photographs of the cerebral cortex during experiments, and flow velocity was measured using transcranial Doppler sonography. Dotarizine was administrated by 20 minute intravenous infusion in a dose of 0.05 mg/kg/min. In the first group of animals the infusion was started during normoventilation, in the next group the infusion started during 30th minute of hyperventilation. The most conspicuous data were obtained in experiments conducted in hyperventilated animals where dotarizine abolished the vasoconstrictive effect of hyperventilation. The results suggest that dotarizine has a pronounced effect on basal as well as cortical arteries of the brain.

Effect of flunarizine on the attenuation of baroreflex by transient cerebral ischemia

Baroreflex sensitivity assessed by phenylephrine-induced reflex bradycardia was markedly decreased by 5- an 10-min global cerebral ischemia in anesthetized dogs. Flunarizine, 0.1 and 1 mg/kg i.v., administered 5 min prior to 5-min ischemia, completely inhibited the decrease in baroreflex sensitivity while such a protective effect of the latter dose was incomplete against 10-min ischemia. In contrast, papaverine, 0.5 mg/kg per min i.v., infused for 5 min prior to 5-min ischemia, failed to protect the decrease in baroreflex sensitivity. Flunarizine may possess a certain direct cerebroprotective effect in addition to its cerebrocirculatory effect.

Role of adenosine in cerebral hypoxic hyperemia in the unanesthetized rabbit

The present study was undertaken to determine the importance of adenosine in the cerebrovascular response to hypoxia. The mass spectrometry method was used to investigate local blood flow, tissue pO2 and pCO2 in 3 cerebral structures: caudate nucleus (n = 8), thalamus (n = 5) and hippocampus (n = 5) in unanesthetized, spontaneously breathing rabbits. After having tested the reproducibility of the hypoxic response each animal was exposed twice to moderate hypoxia. I.v. theophylline (10 mg/kg) was administered between the first and second exposures to hypoxia. The principal finding is that in each cerebral region, the vasodilatation induced by hypoxia was significantly decreased by pretreatment with theophylline despite the low theophylline dose used. It is concluded that adenosine is partly responsible for the cerebral vasodilatation observed during hypoxia. Several other mechanisms possibly involved in this cerebrovascular response are discussed.

Effects of deoxycoformycin on adenosine, inosine, hypoxanthine, xanthine, and uric acid release from the hypoxemic rat cerebral cortex

The effects of the adenosine deaminase inhibitor, deoxycoformycin, on purine release from the rat cerebral cortex were studied with the cortical cup technique. Deoxycoformycin (5 and 500 micrograms/kg i.v.) enhanced the hypoxia/ischemia-evoked release of adenosine from the cerebral cortex, indicating a marked rise in the adenosine content of interstitial fluid in the cerebral cortex. Inosine and hypoxanthine release were attenuated at the higher dose of deoxycoformycin. Uric acid release into the cortical perfusates was enhanced at the higher dose level. These results demonstrate that low doses of deoxycoformycin can be used to elevate interstitial levels of adenosine in the brain during hypoxia, and to depress the formation of some of its metabolites. The elevation of hypoxia/ischemia-evoked adenosine levels can account for the previously reported potentiation of hypoxia-evoked increases in rat cerebral blood flow after deoxycoformycin administration. The potential therapeutic utility of these findings is discussed.

Local cerebral glucose utilization and local cerebral blood flow in conscious rats after administration of flunarizine

The effects of the calcium entry blocker flunarizine on physiologic variables, local cerebral blood flow (LCBF) and local cerebral glucose utilization (LCGU) were investigated. LCBF and LCGU were determined in 37 anatomically discrete brain regions in lightly restrained, conscious rats, using the quantitative, autoradiographic 14C-iodoantipyrine and 14C-2-deoxyglucose techniques. While 5 mg/kg flunarizine given i.v. did not change any of the measured physiologic variables, flunarizine increased LCBF in nearly all gray matter structures compared with saline-treated controls. LCGU was not changed compared to controls. In control as well as in flunarizine-treated rats coupling between LCGU and LCBF was tight. The ratio of LCBF/LCGU was increased after treatment with flunarizine. The data suggest that under normal physiological conditions the calcium entry blocker flunarizine does not change neuronal activity, but exerts primarily a cerebral vasodilating action.

Indomethacin and ibuprofen enhance anoxia-induced hyperemia in rat brain

Cerebral blood flow (CBF) in the rat was monitored by a venous outflow technique with an extracorporeal circulation, which allows for the continuous recording of CBF over periods of several hours. Following intraperitoneal administration, two non-steroidal anti-inflammatory agents, indomethacin and ibuprofen (0.01 and 0.1 mg/kg) showed a tendency to increase resting CBF and the reactive hyperemia elicited by a brief (24 s) anoxic challenge was potentiated. A third agent, diclofenac sodium, was less effective, enhancing the hyperemic response only at the higher (0.1 mg/kg) dose level. The results indicate that indomethacin and ibuprofen may be of value in the treatment of diseases involving cerebrovascular insufficiency.

Flunarizine limits hypoxia-ischemia induced morphologic injury in immature rat brain

We examined the impact of pre-treatment with the calcium antagonist flunarizine on the development of hypoxic-ischemic brain injury in the immature rat. Unilateral carotid artery ligation and subsequent exposure to 2 hours of 8% oxygen in 7-day-old rats was used as a model for perinatal hypoxic-ischemic encephalopathy. This procedure leads to atrophy in the cerebral hemisphere ipsilateral to carotid occlusion, with prominent foci of neuronal infarction in the caudate-putamen (striatum). The morphologic injury develops after 1 1/2 hours of hypoxia; and there is an equivalent time threshold for duration of hypoxic exposure needed to acutely stimulate dopamine release in the ipsilateral striatum. Parenteral administration of 30 mg/kg of flunarizine before hypoxic exposure limited both the release of dopamine acutely and the extent of morphologic damage observed two weeks after the insult. Oral administration of 30 mg/kg of flunarizine in a different vehicle prevented morphologic damage but had no effect on stimulated dopamine release. The drug vehicle for the parenteral preparation also prevented tissue injury, but to a lesser degree than flunarizine. However the parenteral vehicle was equipotent with parenteral flunarizine in limiting acute stimulation of dopamine release. The results demonstrate that flunarizine has potent neuroprotective properties against morphologic brain injury from hypoxia-ischemia, acting by a mechanism which is independent of effects on dopamine release.